Crossmark Global Holdings Inc. Lowers Stock Holdings in Insulet Co. (NASDAQ:PODD)

Crossmark Global Holdings Inc. cut its holdings in Insulet Co. (NASDAQ:PODD) by 9.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,133 shares of the medical instruments supplier’s stock after selling 344 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Insulet were worth $730,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Sei Investments Co. increased its holdings in Insulet by 16.2% in the 1st quarter. Sei Investments Co. now owns 11,782 shares of the medical instruments supplier’s stock worth $2,019,000 after acquiring an additional 1,639 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Insulet by 3.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 78,435 shares of the medical instruments supplier’s stock worth $13,444,000 after purchasing an additional 2,847 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Insulet by 22.3% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 78,391 shares of the medical instruments supplier’s stock worth $13,436,000 after purchasing an additional 14,289 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its stake in Insulet by 246.2% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 135,547 shares of the medical instruments supplier’s stock valued at $23,168,000 after buying an additional 96,390 shares in the last quarter. Finally, Intech Investment Management LLC boosted its holdings in Insulet by 113.8% in the 1st quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock worth $1,140,000 after buying an additional 3,539 shares during the last quarter.

Insulet Trading Down 0.4 %

Shares of Insulet stock opened at $260.12 on Friday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market capitalization of $18.25 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 4.11 and a beta of 1.22. The stock has a 50 day moving average of $237.77 and a 200 day moving average of $207.47.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on PODD shares. Piper Sandler raised their target price on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Barclays raised their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Citigroup lifted their target price on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Sanford C. Bernstein started coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Finally, Raymond James boosted their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.